Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG400549 (Nilofabicin) in MRSA cABSSSI
NCT01593761Phase 2Completed
- Sponsor
- Crystal Genomics
- Start
- Jun 2012
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilofabicin in acute bacterial skin and skin structure infection (ABSSSI), sponsored by Crystal Genomics. Started Jun 2012; status: completed.
02
Drugs
nilofabicin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT01593761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01593761.